Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 779

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 779
---
�basic and diluted                | ​    | ​ | ​                               | $ |   -12,476 | ​ | ​    | ​ | ​ | $ |   -28,032 | ​ | ​    | ​ | ​                              | $ |   -63,188 | ​ | ​    | ​ | ​ | $ |   -86,176 | ​ | ​ |
| Weighted-average common shares outstanding: | ​    | ​ | ​                               | ​ |         ​ | ​ | ​    | ​ | ​ | ​ |         ​ | ​ | ​    | ​ | ​                              | ​ |         ​ | ​ | ​    | ​ | ​ | ​ |         ​ | ​ | ​ |
| Basic and diluted                           | ​    | ​ | ​                               | ​ | 4,570,320 | ​ | ​    | ​ | ​ | ​ | 4,519,641 | ​ | ​    | ​ | ​                              | ​ | 4,559,944 | ​ | ​    | ​ | ​ | ​ | 4,503,187 | ​ | ​ |
| Net loss per share, basic and diluted:      | ​    | ​ | ​                               | $ |     -2.73 | ​ | ​    | ​ | ​ | $ |     -6.20 | ​ | ​    | ​ | ​                              | $ |    -13.86 | ​ | ​    | ​ | ​ | $ |    -19.14 | ​ | ​ |

As of September 30, 2024, 354,964 stock options and 80,660 restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive as a result of the net loss for the period.

F-25

TABLE OF CONTENTS

#### CARA THERAPEUTICS, INC.

### NOTES TO CONDENSED FINANCIAL STATEMENTS
<div align='center'>**(amounts in thousands, except share and per share data) 
 (unaudited)**</div>

As of September 30, 2023, 670,074 stock options and 64,643 restricted stock units were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive